Site Archives
by page:
by month:
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
by post:
- In Conversation with Matt Dolan
- Pluristem to expand R&D of radiation exposure treatment
- Rodman ups Alnylam price target to $19
- D. Medical CEO interviewed on Bloomberg TV
- Cipher achieves sales milestone for Lipofen
- GeneNews in pact for first personalized medicine center in China
- BioLineRx in-licenses second oral Hepatitis C treatment
- pSivida CEO to participate at glaucoma conference
- Rodman to launch automated electronic transaction platform
- Navidea to seek approval for Lymphoseek in Europe
- Roth upgrades Antares Pharma to buy
- Isotechnika ends existing license accord with ILJIN
- BioSante exploring in-licensing and M&As
- enGene initiates $20 million financing to advance lead product
- Health Canada accepts Cipher acne filing for review
- Roth upgrades Spectrum to buy
- Navidea signs option to license PD imaging agent
- Roth starts Intellipharmaceutics at buy
- D. Medical inks fifth U.S. distributor of diabetic infusion sets
- enGene establishes clinical advisory board
- BioLineRx in development pact with Genoscience
- TearLab Osmolarity System gets CLIA Waiver from FDA
- Alitair builds value without outside investors
- Amorfix closes first tranche of private financing
- Trbovich joins C.K. Cooper’s healthcare research team
- Pluristem gets $2.4 Million grant from Israel
- D. Medical expands U.S. distribution of infusion sets
- Novadaq partnering strategy hits marketing milestone
- D. Medical gets CE Mark for insulin pump
- CytoSorbents year-end letter to shareholders
- CytoSorbents to present at OneMedForum
- Cynapsus readies first human data of sublingual strip for PD
- Cynapsus confirms Parkinson’s treatment in drug trial
- Thallion Completes Patient Enrollment of Phase II SHIGATEC Trial
- ILJIN considering control position in Isotechnika
- Zacks starts Cipher at outperform
- Navidea arranges debt financing from Hercules
- D. Medical infusion set listed in ADA consumer guide
- Isotechnika in license pact with Vifor Pharma
- Brainsway TMS device to be distributed in Chile
- BioLineRx partner starts trial for BCM (BL-1040)
- Maquet to distribute Novadaq’s CO2 Heart Laser in U.S.
- Cynapsus arranges debenture financing
- Season’s Greetings (and JPM)
- Cynapsus closes Adagio acquisition
- Cipher gets complete response for amended NDA
- JMP starts Novadaq at market outperform
- Diamedica humanizes Type 2 diabetes monoclonal antibody
- Northwest Biotherapeutics nearing inflection point
- Donald Wyatt joins Isotechnika board
- Roth figures Somaxon parts worth more than the whole
- Northwest Biotherapeutics refutes patent assertions
- David Bupp to retire from Neoprobe board
- Cynapsus arranges debenture financing
- BioSante to seek in-licensing of products
- CytoSorbents awarded U.S. Army SBIR trauma grant
- CMS approves TearLab’s reconsideration request
- Alnylam presents new data on RNAi therapeutics at ASH
- BioLineRx to develop Compugen’s novel peptide drug candidates
- Amorfix arranges private placement of up to $1-million
- Neoprobe licenses AstraZeneca imaging agent
- CytoSorbents in stock sale pact with Lincoln Park Capital
- Neoprobe to change name to Navidea Biopharmaceuticals
- Neoprobe participating at investor conferences
- Roth ups TearLab price target to $3
- BioLineRx posts positive Phase 1a results in neuropathic pain
- Ontario fund invests $1 million in Interface Biologics
- TearLab taps social media for dry eye awareness
- DiaMedica study shows DM-199 increases C-peptide levels
- D. Medical expands U.S. distribution for infusion sets
- FDA grants CLIA-waiver for TearLab osmolarity test
- Northwest Bio implements balance sheet clean-up
- Study shows DiaMedica’s DM-204 lowers stroke risk
- Roth starts TearLab at buy
- Novadaq in sales and marketing pact with Kinetic
- TearLab to present at Piper Jaffray Healthcare Conference
- Diamedica forms advisory group for diabetes products
- BioSante issued new LibiGel method of use patent
- Alnylam completes enrollment in Phase 2b study of RSV Infection
- Viking’s 3DHD vision system featured at UK conference
- Amorfix turnaround builds broad pipeline
- Roth adds Synovis to focus list
- D. Medical issued U.S. patent
- Dr. Paul Marks joins Cellceutix SAB
- Cipher amends NDA for CIP-Isotretinoin acne drug
- Pluristem Therapeutics issues letter to shareholders
- India approves start of BioLineRx Clarity trial
- Cellceutix’s potential breakthrough in cancer research
- Alnylam presents positive preliminary data for ALN-TTR01
- Viking Systems names Zappas VP of U.S. Sales
- BioSante added to NASDAQ Biotechnology Index
- Ventrus acquires title to hemorrhoids product
- Rodman sees Neoprobe driving shareholder value
- TearLab continues to gain acceptance amongst thought leaders
- Alnylam grants InterfeRx license to Sylentis
- Amorfix developing ALS diagnostic tool
- BioSante posts additional positive LibiGel pK results
- Burcon NutraScience develops new pea protein isolate
- CytoSorbents encouraged by market reception of CytoSorb
- Neoprobe to present at Lazard conference
Listen to BioTuesdays 
